Gut mRNA tech supercharges vaccine and GLP-1 delivery
From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.
- Published by
- Phys.org
- Evidence type
- Laboratory
From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Phys.org.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.